Alexander J D'Addio

US Patent:

20020099021, Jul 25, 2002

Filed:

Nov 30, 2000

Appl. No.:

09/727042

Inventors:

Ronald Leflein - East Hanover NJ, US
Alexander D'Addio - Piscataway NJ, US

Assignee:

Carter-Wallace, Inc.

International Classification:

A61K031/7028

US Classification:

514/023000

Abstract:

Tannate compositions consisting essentially of carbetapentane tannate and chlorpheniramine tannate which are effective when administered orally for the symptomatic relief of coryza associated with the common cold, sinusitis, allergic rhinitis, unproductive cough and upper respiratory tract conditions are disclosed.

US Patent:

20100152147, Jun 17, 2010

Filed:

Sep 29, 2009

Appl. No.:

12/569548

Inventors:

Dennis Fuge - Somerset NJ, US
John Higson - Plymouth Meeting PA, US
Bryan A. Roecklein - Somerset NJ, US
Gul Balwani - West Windsor NJ, US
Alexander D. D'Addio - Piscataway NJ, US

International Classification:

A61K 31/56
A61K 31/55
A61K 31/549
A61J 1/05
A61J 1/18

US Classification:

514179, 51421705, 5142225, 424464, 604403, 604404

Abstract:

The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also generally relates to pharmaceutical compositions comprising one or more active pharmaceutical ingredients, such as azelastine or pharmaceutically acceptable salts or esters thereof including azelastine hydrochloride, particularly wherein the compositions are provided in unit dosage form. In certain embodiments, the invention provides such unit dosage pharmaceutical compositions comprising azelastine hydrochloride formulated for use as nasal sprays and/or ocular solutions or drops. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g., for the symptomatic relief of a variety of allergic and non-allergic conditions, particularly conjunctivitis, sinusitis, rhinitis and rhinosinusitis. The compositions and methods of the present invention provide significant value in terms of patient acceptability, convenience, and compliance.

US Patent:

20140158117, Jun 12, 2014

Filed:

Aug 23, 2013

Appl. No.:

13/974881

Inventors:

- Somerset NJ, US
Brian D. LAWRENCE - Somerset NJ, US
Gul BALWANI - West Windsor NJ, US
Alexander D. D'ADDIO - Piscataway NJ, US

Assignee:

Meda Pharmaceuticals Inc. - Somerset NJ

International Classification:

A61K 47/26
A61K 31/55

US Classification:

12820014, 51421705

Abstract:

The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions, into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g., for the symptomatic relief of allergic rhinitis, non-allergic vasomotor rhinitis, allergic conjunctivitis, as well as other disorders.